IR@PKUHSC  > 北京大学药学院
学科主题药学
Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes
Dai, Wenbing1,2; Jin, Wu1; Zhang, Junlin1; Wang, Xueqing1; Wang, Jiancheng1; Zhang, Xuan1; Wan, You2; Zhang, Qiang1
关键词combretastatin A-4 doxorubicin octreotide programmed release spatiotemporally controlled co-delivery targeted delivery
刊名PHARMACEUTICAL RESEARCH
2012-10-01
DOI10.1007/s11095-012-0797-2
29期:10页:2902-2911
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
研究领域[WOS]Chemistry ; Pharmacology & Pharmacy
关键词[WOS]CELL LUNG-CANCER ; COMBRETASTATIN A4 PHOSPHATE ; THYROID-CARCINOMA ; TARGETED DELIVERY ; HIGH-AFFINITY ; TUMOR-GROWTH ; SOMATOSTATIN ; DOXORUBICIN ; CHEMOTHERAPY ; THERAPY
英文摘要

Both combretastatin A-4 (CA-4) and doxorubicin (DOX) was loaded in different form in a targeted nanomedicine in order to achieve the active delivery of these two drugs followed by sequentially suppressing tumor vasculature and tumor cells.

Octreotide-modified stealth liposomes loaded with CA-4 and DOX (Oct-L[CD]) were prepared and characterized. Then in vitro release, cellular uptake, in vitro antitumor effect, pharmacokinetics, in vivo sequential killing effect, in vivo antitumor efficacy against somatostatin receptor (SSTR) positive cells, as well as the action mechanism of such system, were studied.

A rapid release of CA-4 followed by a slow release of DOX was observed in vitro. The active targeted liposomes Oct-L[CD] showed a specific cellular uptake through ligand-receptor interaction and a higher antitumor effect in vitro against SSTR-positive cell line. The in vivo sequential killing effect of such system was found as evidenced by the fast inhibition of blood vessels and slow apoptosis-inducing of tumor cells. Oct-L[CD] also exhibited the strongest antitumor effect in MCF-7 subcutaneous xenograft models.

Oct-modified co-delivery system may have great potential as an effective carrier for cancer therapy.

语种英语
WOS记录号WOS:000308701500020
项目编号81130059 ; 2009CB930300
资助机构National Nature Science Foundation ; National Basic Research Program of China
引用统计
被引频次:26[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62195
专题北京大学药学院
北京大学药学院_药剂学系
作者单位1.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Peking Univ, Sch Basic Med Sci, Neurosci Res Inst, Dept Neurobiol, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Dai, Wenbing,Jin, Wu,Zhang, Junlin,et al. Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes[J]. PHARMACEUTICAL RESEARCH,2012,29(10):2902-2911.
APA Dai, Wenbing.,Jin, Wu.,Zhang, Junlin.,Wang, Xueqing.,Wang, Jiancheng.,...&Zhang, Qiang.(2012).Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes.PHARMACEUTICAL RESEARCH,29(10),2902-2911.
MLA Dai, Wenbing,et al."Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes".PHARMACEUTICAL RESEARCH 29.10(2012):2902-2911.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Dai, Wenbing]的文章
[Jin, Wu]的文章
[Zhang, Junlin]的文章
百度学术
百度学术中相似的文章
[Dai, Wenbing]的文章
[Jin, Wu]的文章
[Zhang, Junlin]的文章
必应学术
必应学术中相似的文章
[Dai, Wenbing]的文章
[Jin, Wu]的文章
[Zhang, Junlin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。